Transcriptional regulatory dynamics of the hypothalamic-pituitary-gonadal axis and its peripheral pathways as impacted by the 3-beta HSD inhibitor trilostane in zebrafish (Danio rerio)

Ecotoxicology and Environmental Safety

Volumn 74, Issue 6, 2011, Pages 1461-1470

  Wang, Rong Lin ^a   Bencic, David ^a   Lazorchak, Jim ^a   Villeneuve, Daniel ^a   Ankley, Gerald T ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Biological pathways; HPG axis; Transcription networks; Trilostane

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ENDOCRINE DISRUPTOR; PROTEIN KINASE; RNA; STEROID; TRANSCRIPTION FACTOR; TRILOSTANE;

ENZYME ACTIVITY; FISH; GENE EXPRESSION; INHIBITION; RNA; STEROID; TOXICOLOGY;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MALE; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEROIDOGENESIS; TOXICITY TESTING; TRANSCRIPTION REGULATION; UPREGULATION; ZEBRA FISH;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; DIHYDROTESTOSTERONE; ENDOCRINE DISRUPTORS; ENDOCRINE SYSTEM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GONADS; HYPOTHALAMUS; MALE; PITUITARY GLAND; UP-REGULATION; WATER POLLUTANTS, CHEMICAL; ZEBRAFISH; ZEBRAFISH PROTEINS;

DANIO RERIO;

EID: 79961127807     PISSN: 01476513     EISSN: 10902414     Source Type: Journal    
DOI: 10.1016/j.ecoenv.2011.05.001     Document Type: Article

References (50)

1. Ankley G.T., Johnson R.D. Small fish models for identifying and assessing the effects of endocrine-disrupting chemicals. ILAR J. 2004, 45:469-483.
2. Ankley G.T., Jensen K.M., Kahl M.D., Makynen E.A., Blake L.S., Greene K.J., Johnson R.D., Villeneuve D.L. Ketoconazole in the fathead minnow (Pimephales promelas): reproductive toxicity and biological compensation. Environ. Toxicol. Chem. 2007, 26:1214-1223.
3. Ankley G.T., Bencic D.C., Breen M.S., Collette T.W., Conolly R.B., Denslow N.D., Edwards S.W., Ekman D.R., Garcia-Reyero N., Jensen K.M., Lazorchak J.M., Martinovic D., Miller D.H., Perkins E.J., Orlando E.F., Villeneuve D.L., Wang R., Watanabe K.H. Endocrine disrupting chemicals in fish: Developing exposure indicators and predictive models of effects based on mechanism of action. Aquat. Toxicol. 2009, 92:168-178.
4. Barker S., Malouitre S.D.M., Glover H.R., Puddefoot J.R., Vinson G.P. Comparison of effects of 4-hydroxy tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: up-regulation of oestrogen receptor beta. J. Steroid Biochem. Mol. Biol. 2006, 100:141-151.
5. Benjamini B., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 1995, 57:289-300.
6. Chipuk J.E., Cornelius S.S., Pultz N.J., Jorgenson J.S., Bonham M.J., Kim S.J., Danielpour D. The androgen receptor represses transforming growth factor-Β signaling through interaction with Smad3. J. Biol. Chem. 2002, 277:1240-1248.
7. Daftary G.S., Taylor H.S. Endocrine regulation of HOX genes. Endocr. Rev. 2006, 27:331-355.
8. Diamanti-Kandarakis E., Bourguignon J.-P., Giudice L.C., Hauser R., Prins G.S., Soto A.M., Zoeller R.T., Gore A.C. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr. Rev. 2009, 30:293-342.
9. Dimova D.K., Dyson N.J. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005, 24:2810-2826.
10. Delpuech O., Griffiths B., East P., Essafi A., Lam E.W., Burgering B., Downward J., Schulze A. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol. Cell. Biol. 2007, 27:4917-4930.
11. Feng X., Derynck R. Specificity and versatility in TGF-Β signaling through Smads. Annu. Rev. Cell Dev. Biol. 2005, 21:659-693.
12. Gabig T.G., Crean C.D., Klenk A., Long H., Copeland N.G., Gilbert D.J., Jenkins N.A., Quincey D., Parente F., Lespinasse F., Carle G.F., Gaudray P., Zhang C.X., Calender A., Hoeppener J., Kas K., Thakker R.V., Farnebo F., Teh B.T., Larsson C., Piehl F., Lagercrantz J., Khodaei S., Carson E., Weber G. Expression and chromosomal localization of the Requiem gene. Mamm. Genome 1998, 9:660-665.
13. Gordon S., Akopyan G., Garban H., Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006, 25:1125-1142.
14. Hitchens M.R., Robbins P.D. The role of the transcription factor DP in apoptosis. Apoptosis 2003, 8:461-468.
15. Hooks S.B., Cummings B.S. Role of Ca2+-independent phospholipase A2 in cell growth and signaling. Biochem. Pharmacol. 2008, 76:1059-1067.
16. Hurlin P., Huang J. The MAX-interacting transcription factor network. Semin. Cancer Biol. 2006, 16:265-274.
17. Jaccard P. Étude comparative de la distribution florale dans une portion des Alpes et des Jura. Bull. Soc. Vaudoise Sci. Nat. 1901, 37:547-579.
18. Ji G.D., Zhou L., Wang Y., Xia W., Gui J.F. Identification of a novel C2 domain factor in ovaries of orange-spotted grouper (Epinephelus coioides). Comp. Biochem. Physiol. 2006, 143:374-383.
19. Kataoka K., Yoshitomo-Nakagawa K., Shioda S., Nishizawa M. A set of Hox proteins interact with the Maf oncoprotein to inhibit its DNA binding, transactivation, and transforming activities. J. Biol. Chem. 2001, 276:819-826.
20. Kang J.S., Liu C., Derynck R. New regulatory mechanisms of TGF-Β receptor function. Trends Cell Biol. 2009, 19:385-394.
21. Kim T.D., Shin S., Janknecht R. Repression of Smad3 activity by histone demethylase SMCX/JARID1C. Biochem. Biophys. Res. Commun. 2008, 366:563-567.
22. Komanicky P., Spark R.F., Melby J.C. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J. Clin. Endocrinol. Metab. 1978, 47:1042-1051.
23. Lavoie H.A., King S.R. Transcriptional regulation of steroidogenic genes: STARD1, CYP11A1 and HSD3B. Exp. Biol. Med. 2009, 234:880-907.
24. Lim W.K., Eugenia L., Califano A. Master regulators used as breast cancer metastasis classifier. Pac. Symp. Biocomput. 2009, 14:504-515.
25. Malouitre S.D.M., Barker S., Puddefoot J.R., Jalili J., Glover H.R., Vinson G.P. Regulation of hepatic steroid receptors and enzymes by the 3Β-hydroxysteroid dehydrogenase inhibitor trilostane. J. Steroid Biochem. Mol. Biol. 2006, 101:97-105.
26. Matsuda T., Yamamoto T., Muraguchi A., Saatcioglu F. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J. Biol. Chem. 2001, 276:42908-42914.
27. Moens C.B., Selleri L. Hox cofactors in vertebrate development. Dev. Biol. 2006, 291:193-206.
28. Pawitan Y., Michiels S., Koscielny S., Gusnanto A., Ploner A. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 2005, 21:3017-3024.
29. Payne A.H., Hales D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev. 2004, 25:947-970.
30. Pendaries V., Verrecchia F., Michel S., Mauviel A. Retinoic acid receptors interfere with the TGF-Β/Smad signaling pathway in a ligand-specific manner. Oncogene 2003, 22:8212-8220.
31. Potthoff M.J., Olson E.N. MEF2: a central regulator of diverse developmental programs. Development 2007, 134:4131-4140.
32. Potts G.O., Creange J.E., Hardomg H.R., Schane H.P. Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 1978, 32:257-267.
33. Rawlings J.S., Rosler K.M., Harrison D.A. The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117:1281-1283.
34. Sala A. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur. J. Cancer 2005, 41:2479-2484.
35. Simard J., Ricketts M.L., Gingras S., Soucy P., Feltus F.A., Melner M.H. Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr. Rev. 2005, 26:525-582.
36. Simmons S.O., Fan C.Y., Ramabhadran R. Cellular response pathway system as a sentinel ensemble in toxicological screening. Toxicol. Sci. 2009, 111:202-225.
37. Subramanian A., Tamayo P., Mootha V.K., Mukherjeed S., Eberta B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
38. Touitou Y., Auzeby A., Bogdan A., Luton J.P., Galan P. 11 beta-hydroxy-11-ketosteroids equilibrium, a source of misinterpretation in steroid synthesis: evidence through the effects of trilostane on 11 beta-hydroxysteroid dehydrogenase in sheep and human adrenals in vitro. J. Steroid. Biochem. 1984, 20:763-768.
39. Vaquerizas J.M., Kummerfeld S.K., Teichmann S.A., Luscombe N.M. A census of human transcription factors: function, expression and evolution. Nat. Rev. Genet. 2009, 10:252-263.
40. Villeneuve D.L., Knoebl I., Kahl M.D., Jensen K.M., Hammermeister D.E., Greene K.J., Blake L.S., Ankley G.T. Relationship between brain and ovary aromatase activity and isoform-specific aromatase mRNA expression in the fathead minnow (Pimephales promelas). Aquat. Toxicol. 2006, 76:353-368.
41. Villeneuve D.L., Larkin P., Knoebl I., Miracle A.L., Kahl M.D., Jensen K.M., Makynen E.A., Durhan E.J., Carter B.J., Denslow N.D., Ankley G.T. A graphical systems model to facilitate hypothesis-driven ecotoxicogenomics research on the brain-pituitary-gonadal axis. Environ. Sci. Technol. 2007, 40:321-330.
42. Villeneuve D.L., Blake L.S., Brodin J.D., Cavallin J.E., Durhan E.J., Jensen K.M., Kahl M.D., Makynen E.A., Martinovic D., Mueller N.D., Ankley G.T. Effects of a 3Β-hydroxysteroid dehydrogenase inhibitor, trilostane, on the fathead minnow reproductive axis. Toxicol. Sci. 2008, 104:113-123.
43. Villeneuve D.L., Mueller N.D., Martinovic D., Makynen E.A., Kahl M.D., Jensen K.M., Durhan E.J., Cavallin J.E., Bencic D., Ankley G.T. Direct effects, compensation, and recovery in female fathead minnows exposed to a model aromatase inhibitor. Environ. Health Perspect. 2009, 117:624-631.
44. Villeneuve D.L., Wang R.L., Bencic D.C., Biales A.D., Martinovic D., Lazorchak J.M., Toth G., Ankley G.T. Altered gene expression in the brain and ovaries of zebrafish exposed to the aromatase inhibitor fadrozole: microarray analysis and hypothesis generation. Environ. Toxicol. Chem. 2009, 28:1767-1782.
45. Wang R.L., Biales A., Bencic D., Lattier D., Kostich M., Villeneuve D., Ankley G.T., Lazorchak J., Toth G. DNA microarray application in ecotoxicology: experimental design, microarray scanning, and factors affecting transcriptional profiles in a small fish species. Environ. Toxicol. Chem. 2008, 27:652-663.
46. Wang R.L., Bencic D., Villeneuve D.L., Ankley G.T., Lazorchak J., Edwards S. A transcriptomics-based biological framework for studying mechanisms of endocrine disruption in small fish species. Aquat. Toxicol. 2010, 98:230-244.
47. World Health Organization (WHO) Global assessment of the state-of-the-science of endocrine disruptors. International Programme on Chemical Safety 2002, WHO/PCS/EDC/02.2. T. Damstra, S. Barlow, A. Bergman, R. Kavlock, G. Van Der Kraak (Eds.).
48. Wilsker D., Probst L., Wain H.M., Maltais L., Tucker P.W., Moran E. Nomenclature of the ARID family of DNA-binding proteins. Genomics 2005, 86:242-251.
49. Zhang Y., Dufau M. Gene silencing by nuclear orphan receptors. Vitam. Horm. 2004, 68:1-48.
50. Zeeberg B.R., Qin H.-Y., Narasimhan S., Sunshine M., Cao H., Kane D.W., Reimers M., Stephens R.M., Bryant D., Burt S.K., Elnekave E., Hari D.M., Wynn T.A., Cunningham-Rundles C., Stewart D.M., Nelson D., Weinstein J.N. High throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of common variable immune deficiency (CVID). BMC Bioinform. 2005, 6:168-186.